A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
Open label single arm phase II study of Pemetrexed plus Oxaliplatin in patients with advanced
gastric carcinoma not previously treated with palliative chemotherapy. 43 Patients will be
enrolled in this local trial. The primary objective of this study is to determine the
response rate of the treatment.Schedule for this study is as follows: 6 cycles/21 days of
Pemetrexed 500 mg/m2 followed by Oxaliplatin 120 mg/m2. This study will also include
pharmacogenomic and pharmacogenetic investigations in order to assess determinants of
efficacy and toxicity of the treatment with Pemetrexed and Oxaliplatin in the study
population.